BEIJING PROTGEN LTD.
4Patents
4Active
4Granted
43Portfolio score
Filing activity: Mar 28, 2012 → Nov 10, 2017
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US10647968B2 | Endostatin mutants with mutations at ATP binding sites | Emerging Cross-Sectional Technologies | 0 | Active |
| US10869910B2 | Molecular design of recombinant protein drug | Chemistry; Metallurgy | 0 | Active |
| US9364493B2 | Methods and compositions for enhancing the uptake of therapeutic agents by target cells | Human Necessities | 0 | Active |
| US11098104B2 | Pegylated endostatin analogue and application thereof | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.